Runner Up: Incidence of Cutaneous Adverse Events with PI3K-Akt-mTOR Pathway Inhibitors: A Systematic Review and Network Meta-Analysis. J of Skin. 2022;6(3):s39. doi:10.25251/skin.6.supp.39